# Medical Devises Regulation in Zimbabwe: An Evaluation of operational readiness

- 3 Charles Chiku<sup>1</sup>, Talkmore Maruta<sup>2</sup>, Fredrick Mbiba<sup>3</sup>, Justen Manasa<sup>4</sup>
- <sup>1</sup> Regulation and Prequalification Department, World Health Organization, Geneva,
   Switzerland
- <sup>6</sup> <sup>2</sup> Programs, African Society for Laboratory Medicine, Lusaka, Zambia
- <sup>3</sup> Biomedical Research and Training Institute, The Health Research Unit, Harare, Zimbabwe
- <sup>4</sup> Department of Oncology, Faculty of Medicine and Health Sciences, University of
- 9 Zimbabwe, Harare, Zimbabwe

Background: Regulation of medical devices has seriously lagged, especially in Resource-10 Limited Settings (RLS). There are disparities in regulating medical devices; in the African 11 region, it is below the global average. This may translate into poor access to quality-assured 12 medical devices and result in undesirable health outcomes. Operational readiness to regulate 13 medical devices in Zimbabwe at the Medicines Control Authority of Zimbabwe (MCAZ), the 14 15 designated National Regulatory Authority (NRA), is vital for planning and implementation. The study aimed to assess the readiness of the MCAZ to regulate medical devices by 16 identifying the strengths and gaps and proposing an institutional development plan that can be 17 18 monitored and evaluated to assess progress over time.

- Methods: Quantitative study was conducted using the World Health Organization (WHO) 19 20 Global Benchmarking Tool+ medical devices (GBT+ medical devices) methodology to evaluate the medical devices regulatory oversight at the MCAZ. Data were collected between 21 June and August 2022 using standard checklists to assess the quality of implementation of 22 23 medical devices' regulatory functions; National Regulatory System (RS), Registration and Market Surveillance and Control (MC), Market Authorisation (MA), Vigilance (VL), 24 Licensing Establishment (LI), Regulatory Inspection (RI), Laboratory Testing(LT), and 25 26 Clinical Trials (CTs) Oversight.
- Results: The MCAZ attained maturity level 1, with an RS score of 79%, MA- 44%, VL -27%,
  MC- 40%, LI- 62%, RI- 68%, LT- 88%, and CT -18%. Condoms and gloves were the only
  regulated medical devices. Indicators on legal provisions, regulations, and guidelines across
  the regulatory functions were below the optimum requirement.
- Conclusion: The legal provisions, regulations, and guidelines are inadequate for effectively regulating medical devices. The medical devices regulation requires review for it to be robust and fit-for-purpose, responsive, oriented to the outcome, predictable based on a standard and transparent approach, and the level of scrutiny proportionate to the risk classification of the medical device.
- 36

#### 37 Key Words:

- 38 Medical Devices, Safety, Quality, Performance, National Regulatory System, Registration and
- 39 Market Authorisation, Vigilance, Market Surveillance and Control, Licensing Establishment,
- 40 Regulatory Inspection, Laboratory Testing, and Clinical Trials. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

41

# 42 Introduction

Medical devices are essential for the public to reach the highest health standards. Although regulations for medicines and vaccines have existed for many years, regulation of medical devices, including In Vitro Diagnostics (IVDs) medical devices, has seriously lagged, especially in resource-limited settings (RLS). A medical device is "any instrument, apparatus, machine, appliance, implant, reagent for in vitro use, software, material, or related article used for a specific medical purpose" (1,2). An IVD medical device is used to examine human specimens to provide diagnostic information, monitoring, or compatibility purposes (3).

- 50
- 51

#### **Medical Device Regulations**

52 Medical Device Regulations are a set of laws and regulations governing clinical trials, 53 manufacturing, and distribution of medical devices to ensure they are safe and perform as 54 intended by their manufacturers (4,5). The primary objective of regulating medical devices is 55 to facilitate access to safe, effective medical devices with acceptable performance and quality 56 to ensure safety for patients and users.

57

Regulatory processes in the African region are not well documented compared to the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (6). However, despite the regulatory processes being well documented in the US and the EU, they have not been immune to challenges associated with product recalls, adverse incident reports and removing some medical devices from the market (7,8). These systems are not easily adoptable by RLS due to their prohibitively high maintenance costs and the capacity required to ensure continuous improvement. Harmonising regulatory systems across different settings

is essential to reduce the regulatory burden on manufacturers and other economic operators in
getting their products on the market. It has also been concluded that poor regulatory systems
in developing countries make it difficult for manufacturers to introduce their products in these
markets, resulting in limited access to them (9,10).

69

In general, there are mechanisms to reduce the regulatory burden on manufacturers and the 70 71 workload on the regulators. These include convergence, harmonisation, reliance and recognition. Convergence is an approach that seeks to make regulatory requirements similar 72 73 across countries and adopt internationally recognised standards, technical guidance documents, shared scientific principles and procedures to ensure that public health is protected considering 74 the local context. It does not necessarily mean the harmonisation of laws. Harmonisation is the 75 process by which technical guidelines are developed to be uniform across participating 76 77 authorities. Reliance is the act whereby the regulatory authority in one jurisdiction takes into account and bases its decision on an evaluation conducted by another regulatory authority. In 78 contrast, the relying authority remains responsible for its decisions. The reliance mechanism is 79 meant to reduce the barriers to access of IVDs due to unclear regulations and a lack of legal 80 provisions to implement it. Regulatory reliance enables healthcare systems to; 81

• accelerate global access to safe and quality health technology,

• increase efficient use of resources and avoid duplication of efforts,

• reduce uncertainties for innovators and improve harmonisation in regulation,

• promote more consistent and robust responses to crises (2).

Recognition is a mechanism that allows approval from one regulatory authority to be given
equivalent weight in another jurisdiction. Recognition indicates that evidence of conformity
with the regulatory requirements of country X is sufficient to meet country Y(11).

89

90

#### 91

#### **Disparities in Medical Device Regulations**

There are disparities in the availability of medical device regulatory services between the global 92 and WHO Africa (Afro) region. About 40% of countries in the WHO Afro region had no 93 regulations for medical devices, 32% had some regulations, and 28% had no regulations. 94 In contrast, at the global level, 58% of all WHO member states indicated that they had 95 96 regulations on medical devices. Zimbabwe was presented with the element of only placing medical devices on the market. Premarket and post-market elements were unavailable 97 98 according to the survey published in 2016 by the WHO(12). This gap in medical device regulation between the Afro region and the global average is crucial as it may translate to lower-99 quality medical devices and limited patient access to healthcare technologies. The lack of 100 101 harmonised regulations may result in a regulatory burden for manufacturers to introduce their products on the market. The fundamental characteristics of a robust and fit-for-purpose 102 regulatory system are responsiveness, oriented to the outcome, predictability based on a 103 standard and transparent approach, and the level of scrutiny to assess the conformity of the 104 medical devices to set requirements must be proportionate to the risk classification of the 105 medical device. The regulatory system and institutions must be independent (13). 106

107

#### 108 Medical Device, including IVD Regulations in Zimbabwe

There is a dearth of medical device literature specific to Zimbabwe. Hubner et al. conducted a study to determine the evolving landscape of medical device regulations in member countries of the Surgeons of Central, Eastern and Southern Africa (COSECA). Zimbabwe is a member of COSECA. The study used a systematic review of the literature on medical devices. It was concluded that Zimbabwe had a legal framework for regulating medical devices, conformity assessment (evaluation conducted to approve medical devices to be granted market access),

and import and export and post-market surveillance for condoms and gloves only (9). Contrary to the finding, the WHO survey concluded that Zimbabwe only had elements of placing medical devices on the market without premarket and post-market elements. It is unclear whether the framework in Zimbabwe has evolved and is robust enough to effectively regulate medical devices, including IVDs.

120

121 Another study conducted by Mwedzi et al. in monitoring the progress in regulatory systems strengthening in the Southern African Development Community (SADC)-Zimbabwe is a 122 123 member state of SADC. It was determined that the NRAs with a normative legal framework for medical devices were just above 50%, and less than 50% of the member states had a legal 124 framework for regulating IVD medical devices or imaging equipment. The study looked at 125 premarket approval, to a lesser extent, clinical testing and post-marketing surveillance (13). 126 Furthermore, the results lacked granularity since they were anonymised and unlinked, making 127 it difficult to conclude the regulatory status of Zimbabwe. 128

129

Similarly, Kniazkov et al. surveyed to map existing frameworks, mechanisms and approaches to prevention, detection and response (PDR) to Sub-Standard and Falsified (SF) medical products. Findings pointed to deficiencies in policies and implementation plans despite most countries having the mandate and legislation to deal with substandard and falsified (SF) medical products. This study also lacked specific results for Zimbabwe due to unlinking and anonymising the countries. Moreover, the study was for medical products in general without specifying medical devices (14).

137

A qualitative study to assess the regulation of HIV-Self Testing IVDs in Malawi, Zambia and
Zimbabwe was conducted by Dacombe et al. The study aimed to document the emerging

regulatory landscape and perceptions of key stakeholders involved in HIVST policy and 140 regulation before implementation in three low- and middle-income countries. It was found that 141 the reference laboratory monitored the quality and performance of HIV-Self Testing IVDs used 142 in the public sector in all three countries. However, the mandate to regulate HIV-Self Testing 143 IVDs overlapped between the Medical Laboratory and Clinical Scientists Council of 144 Zimbabwe and the Medicines Control Authority of Zimbabwe (MCAZ). Stakeholders 145 146 indicated they had a poor understanding of the process and requirements for HIVST regulation and a lack of clarity and coordination between organisational roles (15). 147

148

The extent to which Zimbabwe's regulatory system governance is an essential driver for 149 implementation has yet to be adequately appraised due to a lack of studies specific to the 150 Zimbabwean context. Recent studies have shown an absence of medical device regulation 151 literature in the COSECA region. The same study concluded that Zimbabwe had no formal 152 regulatory system for medical devices except for gloves and condoms (9). The study also 153 concluded that MCAZ is a regulatory authority mandated to regulate medical devices. 154 However, another study examining HIV Self-Testing IVDs in Zambia, Malawi and Zimbabwe 155 concluded that it was unclear which institution was mandated to regulate IVDs in Zimbabwe 156 (15). 157

158

Our study aimed to unpack the landscape of medical device regulation in Zimbabwe, focusing on the MCAZ as the NRA using the GBT + medical devices. The GBT tool was created after harmonising benchmarking tools for health products. The harmonisation was conducted to maximise outcomes and reduce the regulatory burden for the NRAs and manufacturers. The GBT is "a game changer in strengthening national regulatory capacity" through a global standardised manner of evaluating regulatory systems (16). An effective regulatory system is essential to strengthening health and improving health outcomes. Better health outcomes for
the population are achieved through access to safe medical devices of acceptable quality,
performance and effectiveness. This is the goal of effective medical device regulation.

On the one hand, due to SF medical devices and associated economic costs, underdeveloped 168 regulatory systems may severely affect public health. Underdeveloped regulatory systems are 169 associated with the regulatory burden for manufacturers to comply with unclear or different 170 171 regulations when seeking premarket approvals in other countries. Therefore, some manufacturers may be reluctant to introduce their medical devices in countries with 172 173 underdeveloped regulatory systems, which makes it difficult for the population to access muchneeded medical devices. Conversely, the respective NRAs must provide balance by ensuring 174 public health and users' protection through approved, safe, effective, acceptable quality and 175 performance medical devices (10). The readiness of the MCAZ to effectively regulate medical 176 devices beyond condoms and gloves is unknown. MCAZ is a statutory body established by 177 Parliament, The Medicines and Allied Substances Control Act (MASCA) [Chapter 15.03], to 178 regulate medicines and Allied Substances. Therefore, benchmarking the MCAZ is crucial in 179 assessing its readiness to regulate medical devices effectively (17). 180

181

The study is significant because Zimbabwe is expanding the regulatory system by expanding 182 the scope of health products regulated to include IVDs. Fundamentally, independent and 183 184 objective benchmarking be conducted to identify strengths and deficiencies. The benchmarking needs to be standardised according to globally acceptable standards. The WHO GBT is one of 185 the globally acceptable ways of benchmarking the maturity level of NRAs (18). The tool uses 186 a set of indicators to evaluate the NRA. It uses it as input in developing a road map to guide 187 establishing, implementing and maintaining an effective medical devices regulatory system. 188 Additionally, the road map works as a tool for the regulatory system to be responsive, 189

predictable, transparent and proportional to the public health risks will ensure the populationaccess to safe and acceptable quality and performance medical devices.

192

# 193 Methods

#### 194 Study design

We conducted a quantitative study using the WHO GBT+ medical devices methodology to evaluate the medical devices regulatory oversight at the MCAZ in Zimbabwe between June and August 2022. The following regulatory functions were assessed following the medical devices' life cycle:

199

- National Regulatory System (RS)- The legal and regulatory framework supports the
   regulatory system's functions to ensure the quality, safety, and performance of medical
   products.
- Registration and Market Authorisation (MA)- The issuance of marketing authorisations
   (also referred to as product licensing or registration) when medical products have met
   the requirements of standardised conformity assessment.
- Vigilance (VL)- The science and activities relating to the prevention, detection,
   assessment, and understanding of adverse effects or any other medical product-related
   problems for guaranteeing that medical product continues to meet quality, safety and
   performance requirements throughout the product's lifecycle.
- Market Surveillance and Control (MC)-The function of assuring ongoing compliance
   of the products placed on the market with quality, safety and performance requirements.
- Licensing Establishment (LE) The function of guaranteeing the quality, safety, and
   performance of medical products used within or exported out of the country through

214 licensing of establishments involved in the value chain and life cycle of the medical215 products.

- Regulatory Inspection (RI)-Auditing establishments throughout the value chain and life
   cycle of medical devices to ensure compliance of these establishments with laws,
   regulations, approved standards, norms, and guidelines.
- Laboratory Testing(LT)- The independent performance verification of the
   manufacturer's performance claims by the NRA to support premarket approval or a
   variation or change to marketing authorisation.
- Clinical Trials (CTs) Oversight- Refers to the legal mandate of the NRA to authorise,
   regulate and, if necessary, terminate CTs.
- 224

225 The regulatory functions were assessed using a set of indicators that were divided into the

- 226 following nine categories:
- 1. Legal provisions, regulations and guidelines.
- 228 2. Organisation and governance.
- 229 3. Policy and strategic planning.
- 230 4. Leadership and crisis management.
- 5. Transparency, accountability and communication.
- 6. Quality and risk management systems.
- 233 7. Regulatory process.
- 8. Resources (including Human, financial, infrastructure, equipment and information
  management systems).
- 236 9. Monitoring progress and assessing impact.

237

238 Sub-indicators are grouped under a parent indicator to compile overall scores (19).

239

240

#### 241 Study setting

The benchmarking of the MCAZ was conducted between June and August 2022 since the institution is a statutory body established to regulate medicines and allied substances according to the Medicines and Allied Substances Control Act (MASCA) [Chapter 15.03].

245

#### 246 Data Analysis

247 Descriptive analysis was performed to describe the quality of regulatory function 248 implementation based on the cumulative score of sub-indicators. The Computerised GBT 249 (cGBT) scoring algorithm was used to determine the implementation status of each indicator 250 for each regulatory function. Scoring was done as a measure of assessing the quality of the 251 implementation of each sub-indicator as follows:

252

# Not implemented (NI): no evidence was provided to demonstrate any degree of implementation of the sub-indicator. This status was assigned where a score of 0% as a percentage is attained.

256 2. Ongoing implementation (OI): some actions/steps/activities were taken towards
257 implementing the concerned sub-indicator. However, the sub-indicator still needs to be
258 implemented in full. A score of 25% was assigned to this category (a score of 25% as
259 a percentage).

Partially implemented (PI): some actions/activities showed the full implementation of
 the sub-indicator; however, such full performance is recent or relatively new, with little
 cumulative data for consistent execution. Supporting documented evidence was
 expected to show the current full implementation of the concerned sub-indicator. For

264 mathematical scoring, 'partially implemented' is scored as 0.75 out of one (i.e., 75% as
265 a percentage).

4. Fully implemented (I): some actions/activities demonstrate the consistent and full
implementation of the sub-indicator over time. Supporting evidence is expected to
illustrate the full, consistent implementation of the sub-indicator (i.e., shown over time
and through repetition of the process and outcome). 'Fully implemented' is scored as
one out of one (i.e., 100% as a percentage).

271

The cGBT algorithm was used to assign maturity levels (MLs) based on the cumulative scoring of the sub-indicators under that function. For a regulatory function to reach a specific ML, a specified percentage of sub-indicators must be scored as 'fully implemented' (19).

275

#### 276 Ethical Considerations

Ethical approval for this study was obtained from the Medical Research Council of Zimbabwe (MRCZ/A/2900). Participation was voluntary. Participants were able to stop the interview at any time without explanation. Written informed consent was obtained from each study participant before each interview. The interview content and the interviewee's identity were kept anonymous.

282

### 283 **Results**

The regulatory functions that were assessed were all at maturity level 1. Maturity level 1 is the minor level to measure each indicator's implementation quality. Figure 1 shows the maturity level of each regulatory function. The Lot Release regulatory function was not assessed because it does not apply to medical devices.

288

The quality of implementation of each regulatory function ranged between 18% to 88%.
Clinical Trial was the least, with 18%, and Laboratory Testing scored 88%. Figure 2 shows the
performance of each regulatory function that was assessed.

292

The national regulatory system function did not have explicit legal provisions and regulations that required medical devices to meet specific safety, quality and performance requirements throughout their lifecycle. Additionally, the MASCA did not define the roles and responsibilities of institutions involved in the medical devices regulatory system. Similarly, there were no legal provisions and relevant regulations to take action on the recall, suspension, withdrawal and destruction of SF medical devices.

299

MA function fell short in legal provisions and regulations that mandate medical devices to be assessed against stipulated requirements before accessing the market. No requirements require medical devices to be subjected to a conformity assessment proportional to the medical device's risk class. Draft IVDs regulations were in place pending approval for implementation.

304

The VL function was not robust enough to prevent, detect, assess, and understand the adverse effects or any other medical device-related problems throughout the medical devices' lifecycle, except for condoms and gloves.

308

Efforts were ongoing to address market surveillance and controls. There were no legal provisions and regulations to control import activities. However, Import and Export regulations for medical devices were in draft format, pending approval. Legal provisions and regulations authorise market surveillance and control activities, including product sampling from different supply chain points, were unavailable. The NRA did not have legal provisions and regulations

to address its role in dealing with SF medical devices.

315

No legal provisions and regulations required economic operators involved throughout the value
chain of medical devices to be registered based on Good Practices (GXP) compliance.
Furthermore, there were no legal provisions to empower the NRA to issue, suspend or revoke
licenses for establishments for medical devices besides condoms and gloves.

320

No legal provisions, regulations or guidelines were required to define the regulatory framework of inspection and enforcement for medical devices, except for condoms and gloves. Additionally, there were no updated national GXP regulations, norms or guidelines that are mandatory to guide economic operators on their submissions.

325

The laboratory testing function was well established and implemented for condoms and gloves. Although the legal basis is unclear, demonstrable steps have been taken towards establishing one for IVD medical devices. In addition, there is no evidence of legal provisions or regulations allowing reliance on and recognition of other laboratories' regulatory decisions.

330

There were no legal provisions or regulations for CT oversight. Moreover, no legal provisions or regulations required notification to and authorisation from the NRA diversions from the original protocol of the CTs. Lastly, there was no evidence of legal provisions, regulations or guidelines requiring that investigational medical products (IMPs) comply with good manufacturing practices for IMPs.

336

Cross-cutting indicators were generally in place; policy and strategic planning, leadership andcrisis management, transparency, accountability and communication, quality and risk

management systems, regulatory process, resources (Human, financial, infrastructure, 339 equipment and information management systems), monitoring progress and assessing impact. 340 However, the indicators were sufficient for regulating condoms and gloves only. There were 341 some vacant staff positions compared to the current establishment of the NRA. The competence 342 framework was sufficient for the existing scope of regulated medical devices (condoms and 343 gloves) but not for other medical devices. Transparency and accountability needed to be 344 345 improved as the NRA was not publishing public reports, excerpts of regulatory assessments conducted (market authorisation, laboratory or inspection reports), and lists of all approved or 346 347 rejected applications.

# 348 **Discussion**

349

350 <u>RS</u>

Medical devices, including IVDs in Zimbabwe, are not adequately regulated due to the low score of less than 80%. The ineffective regulation of these health products is because of an underdeveloped legislative framework. The MASCA was promulgated specifically to regulate medicines and Allied Substances. However, the term "Allied Substances" was not defined, leaving a gap in the scope of products that can be regulated under this legislation. Hubner et al. concluded that the Zimbabwean legislation did not define medical devices (9). Therefore, our finding is consistent with Hubner et al.'s finding.

358

The MCAZ seems not to have a clear mandate to regulate medical devices. The implications are the non-regulation of medical devices because of the undefined regulatory framework for the national regulatory system. Considering no standard definition of medical devices and the 362 lack of a well-defined regulatory framework may have resulted in the unavailability of essential 363 principles of safety and performance and risk-based classification of medical devices, as 364 concluded by Hubner et al. Overall, the maturity level of the regulatory system was found to 365 be ML 1, which is consistent with the conclusion by Hubner et al. that Zimbabwe did not have 366 a formal regulatory process for medical devices, except for some aspects to regulate condoms 367 and gloves (9).

368

The findings clearly show that Zimbabwe's medical devices regulatory system has not been 369 responsive, outcome-oriented, predictable, risk proportionate to public health risk and 370 independent; these are critical characteristics of a robust regulatory system. The finding agrees 371 372 with what Dube-Mwedzi et al. said about efforts to strengthen regulatory frameworks for 373 medicines, whilst focus on medical devices has been lower (13). Yet, poor-quality medical devices significantly impact healthcare outcomes. It is widely accepted now that the value of 374 375 medication rests mainly on the accuracy of the diagnosis. Thus, using poor-quality medical devices and diagnostics undermines the effectiveness of efforts to make good quality, safe and 376 effective medicines available. Investing more efforts into strengthening frameworks for 377 medical devices could be recommended as a priority for the SADC countries. Dube-Mwedzi 378 also stressed the need to strengthen governance to make the national regulatory authority more 379 380 efficient. Looking at the Zimbabwean context, following an institutional approach that involves implementing the "best practices" seems plausible to harmonise the regulations. The other 381 option requires experimentation and prioritisation of country-specific challenges, which may 382 be challenging and costly for countries without experience. The problem-driven approach 383 diverges from the institutional approach by prioritising country-specific issues and 384 enforcement over the blanket implementation of "best practices." This approach allows for 385 feedback loops and greater policy experimentation as problems arise (20). Therefore, the 386

MCAZ must be empowered to regulate medical devices based on a solid legal foundation. The 387 methodology in our study differed from Dube-Mwedzi et al.'s because the latter focused on the 388 389 SADC member states, and the data presented needed to be more granular to identify where Zimbabwe stood in the study. In our study, we had an in-depth look at the Zimbabwean context. 390 391 Furthermore, the methodology in this study looked at registration and licensing (import and 392 export controls), clinical testing and PMS regulatory functions. In addition to the stated 393 394 regulatory functions, the study conducted by this researcher looked further at indicators specific to regulatory systems, market authorisation, Licensing establishment, product performance 395 evaluation, and regulatory inspection and quality management system audits. The findings on 396 397 the additional regulatory functions are stated below. 398 399 400 401 MA The quality of performance for this regulatory function was 44% due to the lack of legal 402 provisions and regulations to mandate the registration of medical devices before accessing the 403 market. The legal provisions, regulations and guidelines for medical devices should also 404 405 support notification/listing low-risk products. The International Medical Devices Regulatory 406 Framework (IMDRF) and its predecessor, the Global Harmonisation Working Party (GHTF), recommend that medical devices be assigned to one of four classes based on a set of rules. This 407

408 assignment determines the level of scrutiny the device is subjected to for conformity 409 assessment. Class A devices offer the lowest risk, Class B low to moderate hazard, Class C

moderate to high risk, and Class D the highest risk. The level of regulatory oversight and the 410 evidence required to support the product's conformity assessment to Essential Principles for 411 Safety and Performance becomes more robust and demanding as the device's classification 412 increases from A to D (21,22). Medical devices other than condoms and gloves are not quality 413 assured and marketed without undergoing a process of evaluation to determine the product's 414 quality, safety, and performance. There is no assurance that only medical devices the NRA has 415 416 duly authorised are allowed to be manufactured, imported, distributed, sold or supplied to end 417 users.

418 <u>VL</u>

The vigilance regulatory function had a quality score of 27% due to the lack of legal provisions, 419 regulations, and guidelines required to define the regulatory framework of vigilance, leaving 420 421 the Zimbabwean population at risk of medical devices that do not continue to meet requirements for quality, safety and performance throughout the product's lifecycle. An 422 423 established, implemented and maintained reporting system must be established to monitor medical device quality, safety and performance. The regulatory function is essential because 424 even mature regulatory jurisdictions such as USFDA and the EU were not spared from adverse 425 incidents and recalls of medical devices, which called for an overhaul of the regulatory system 426 in the EU context (8). These deficiencies imply that the magnitude of adverse events related to 427 medical devices is unknown in the Zimbabwean context. The human and economic costs of 428 these deficiencies can be severe. Legislation must mandate the economic operators 429 (manufacturers, importers, distributors, authorised representatives and wholesalers) to collect 430 and evaluate the experiences gained from medical devices placed on the market. The economic 431 operators must record and investigate any incident report they receive, implement field safety 432 corrective action proportional to the identified deficiency and inform the regulatory authority 433 when the law demands so. Regulators must be informed when there is a severe public health 434

435	threat or when death or serious deterioration in health occurred or may have occurred to the
436	user, patient or another person. The incident may be linked to the medical device's quality,
437	safety or performance. The regulatory authority may monitor the manufacturer's investigation
438	to determine the root cause (4,5).
439	<u>MC</u>
440	An effort has been made to establish import and export regulations for medical devices
441	attaining a 40% score. However, there are no legal provisions concerning import activities,
442	including permanent regulatory intervention at designated entry and exit ports where medical
443	devices are moved. Similarly, there were no legal provisions to authorise market surveillance
444	and control activities, including medical device sampling from different supply chain points.
445	These deficiencies expose the country to SF medical devices and may compromise:
446	• patients' safety and health outcomes,
447	• national economy due to the disease burden,
448	• public trust in the healthcare system, and
449	• the international fight against serious health challenges such as malaria and
450	antimicrobial resistance (23).
451	Additionally, the lack of legal provisions and regulations addressing the role of NRA in dealing
452	with SF medical products makes it challenging to implement this regulatory function at the
453	present moment.
454	There is a shortage in the literature regarding SF medical products in Africa and the Middle
455	East. Studies have been mainly on medicines; this clearly shows that more needs to be done
456	regarding SF medical devices and must be prioritised to ensure acceptable quality, safety and
457	performance of medical devices (23). Challenges in managing medical products have been

458 documented in the SADC region; however, more needs to be known regarding medical devices,

including IVDs. A study conducted to map existing frameworks, mechanisms and approaches 459 to prevention, detection and response (PDR) to SF medical products concluded that most 460 countries had the legal mandate to implement measures to curb SF medical products. Still, they 461 were not doing so (14). Product failures have been reported in the United States (US) and 462 European Union, resulting in regulatory regime reforms. The US and EU regulations are highly 463 esteemed. However, high incidences of clinical adverse events, high recall rates, and frequent 464 465 phase-out of some medical devices have resulted in overhauling the regulations (8). The problem may be more for a country like Zimbabwe that needs legislation to curb SF medical 466 467 devices.

468 <u>*LI*</u>

469 There were no legal provisions, regulations, or guidelines for licensing economic operators 470 along the value chain of medical devices resulting in an overall score of 62%. The score implies that economic operators involved in the medical devices supply chain are not licensed using a 471 472 licensing regime that is proportional to the role in the medical device's value chain and the medical device's risk classification. Consequently, there is no traceability of medical devices 473 throughout the supply chain of medical devices, except for condoms and gloves. The NRA 474 must be empowered by legislation to issue licenses and suspend or revoke establishment 475 permits. In cases of post-licensing changes, the legislation or regulations must require the 476 economic operators to notify the regulatory authority. 477

478 <u>*LT*</u>

The laboratory testing regulatory function had the highest score (88%) due to the lab testing conducted for condoms and gloves, excluding other medical devices, including IVDs. This score may be due to assessments by external bodies since the laboratory is ISO 17025 accredited. However, due to the wide range and complexities of medical devices, medical

devices other than condoms and gloves are not independently verified by laboratory testing 483 where applicable based on the risk class of the medical device. The non-verification for market 484 authorisation, vigilance, market surveillance and control or post-authorisation changes exposes 485 the population to the risk of SF medical devices. Due to the wide range of medical devices and 486 the associated laboratory expertise, the NRA may outsource part or most laboratory testing. 487 The details of the outsourced testing services' responsibilities, duties and roles in these 488 489 structures should be clearly defined and documented, including their accreditation status. The NRA must implement mechanisms to select, monitor and evaluate laboratories performing 490 491 laboratory work before fulfilling the regulatory requirements. The evaluation may be done through onsite audits using ISO 15189 and ISO 17025 requirements to assess policies and 492 procedures for the tests conducted in individual laboratories. Having an ISO accreditation is a 493 good starting point. However, more is needed, as anecdotal evidence has shown that labs that 494 may have ISO 15189 accreditation failed the audit conducted by the WHO for the labs to be 495 listed as WHO Performance Evaluation Laboratories (PEL) for IVDs. 496

Performance evaluation is critical to verify a manufacturer's claims for a medical device. Therefore, it is of paramount importance for the NRA to conduct an assessment and analysis of data to establish or verify the scientific validity, the analytical and, where applicable, the clinical performance of a medical device to ensure that the intended purpose and the classification is appropriate based on the specific disorder, condition or risk factor of interest that it is intended to detect, define or differentiate(4,5).

503 <u>*RI*</u>

The regulatory inspection had an implementation quality score of 68% due to market authorisation inspections conducted for establishments involved in the supply chain of condoms and gloves. However, legal provisions, regulations and guidelines for regulatory 507 inspection were not explicit for medical devices. Establishments involved in other medical 508 devices besides condoms and gloves are unknown regarding compliance with perceived 509 standards. The NRA must publish the list of measures that all the economic operators must 510 comply with, and these standards must be the basis upon which the economic operators are 511 audited for compliance. Regulatory inspection activities must be supported by a comprehensive 512 set of legal provisions, regulations and guidelines which provide the necessary mandate to 513 implement all activities related to this regulatory function.

514 CT Oversight.

The CT oversight regulatory scored the least (18%). The MASCA mentions clinical trials in 515 the context of medicines only, but not for medical devices. Some classes of medical devices 516 require clinical trials to be conducted to support registration and market authorisation of these 517 518 products. Before registration and market authorisation, the products are classified as IMPs. The NRA needs to oversee these products before, during and after the implementation of CTs. The 519 520 NRA must have the legal mandate to authorise, regulate and, if necessary, terminate CTs in line with the international medical research ethics guidelines and principles. Before the trial 521 commences, the NRA should have trained and competent staff to review CT protocols, also 522 reviewed by an Independent Ethics Committee (IEC). The IEC should review the protocols 523 and should have the authority, when necessary, to require protocol revisions. The CT review 524 525 committee should comprise members that are competent and skilled and ensure that there is no conflict of interest. The finding in this study is that there is CT oversight by the NRA for 526 investigational medical devices undergoing CT in Zimbabwe due to the lack of the following: 527

528

• Legal provisions and regulations for CTs oversight.

529	٠	Legal provisions and regulations require research centres, researchers, sponsors,
530		clinical research organisations (CROs) and all relevant institutions in the clinical trial
531		to comply with good clinical practice (GCP).

- Legal provisions and regulations stipulate that authorisation from NRA and notification
   to the NRA are required where there are changes to the original protocol or any relevant
   documents of the CT.
- Legal provisions, regulations and guidelines require that IMPs comply with good
   manufacturing practice (GMP) for IMPs.
- Legal provisions or regulations cover circumstances where the routine CT evaluation
  and procedure may not be followed (e.g. for public-health interests).
- Legal provisions, regulations or guidelines exist for NRA to inspect, suspend or stop
  CTs.

541 These deficiencies subject the Zimbabwean population to products needing acceptable quality,542 safety and performance during CTs.

Furthermore, the NRA is unaware of the CTs conducted and those in progress; the research 543 544 participants' rights are not guaranteed because the participants are uninformed. This is unacceptable today, considering the previous well-documented violations: "Tuskegee Syphilis 545 Study from 1932 to 1972, Nazi medical experimentation in the 1930s and 1940s, and research 546 547 conducted at the Willowbrook State School in the 1950s and 1960s. As the aftermath of these practices, wherein uninformed and unaware patients were exposed to a disease or subject to 548 other unproven treatments, became known, the need for rules governing the design and 549 implementation of human-subject research protocols became very evident." (24). 550

551 Cross-cutting indicators were generally in place; policy and strategic planning, leadership and 552 crisis management, transparency, accountability and communication, quality and risk management systems, regulatory process, resources (Human, financial, infrastructure, equipment and information management systems), monitoring progress and assessing impact. However, the indicators were sufficient for regulating condoms and gloves only. There were some vacant staff positions compared to the current establishment of the NRA. The competence framework was sufficient for the existing scope of products. There is a need to review the operational and competency framework to meet the scope and complexity of other medical devices. The competency framework must include the following aspects:

- Scientific and Health Concepts: Understanding and applying "evolving basic and translational science, regulatory science and public health concepts to drive new approaches to improve healthcare product development, review and oversight" (25)
- Ethics: Ability to integrate and demonstrate core values, integrity and accountability.
- Business Acumen: Ability to successfully leverage systems and processes to operate a
   regulatory function.

# • Communication: Ability to convey or exchange information with stakeholders within and outside the organisation.

- "Leadership: Ability to direct and contribute to initiatives within the organisation, with
   groups engaged in developing good regulatory practice and policy, and within the
   regulatory profession.
- Regulatory Frameworks and Strategy: Knowledge of regulatory frameworks and
   external environments and the ability to apply these to regulatory solutions throughout
   the product lifecycle.
- Product Development and Registration: Knowledge of the research and development,
   preclinical and clinical steps and related regulations in healthcare product development.
- Postapproval/Post-market: Knowledge of requirements and processes for maintaining
- 577 a product on the market, reporting and surveillance"(25,26)

578	The NRA needs to improve mechanisms to promote transparency, accountability and
579	communication by publishing summary technical evaluation reports for approved
580	registration MA, inspections, and rejected applications.

#### 581 Study Limitations

582 The study was conducted in the context of MCAZ as the NRA. However, the Medical

583 Laboratory and Clinical Scientists Council of Zimbabwe and the National Microbiology

584 Reference Laboratory were not benchmarked. The two institutions register IVD Medical for

priority pathogens. The registration is used as an eligibility criterion for products to be

586 procured through the national tendering process.

# 587 Conclusions

The readiness of the NRA in Zimbabwe to regulate medical devices is below optimum as it is 588 at the lowest possible score that can be attained using the GBT+ medical devices methodology. 589 The NRA does not have an explicit legal mandate to regulate medical devices. The MASCA 590 needs more clarity on legal provisions for medical devices regulatory system framework, 591 registration and market authorisation, vigilance, market surveillance control, licensing 592 establishment, regulatory inspection, laboratory testing and clinical trials. The legal provisions, 593 594 regulations, and guidelines are inadequate for effectively regulating medical devices. The medical devices regulation requires review for it to be robust and fit-for-purpose, responsive, 595 oriented to the outcome, predictable based on a standard and transparent approach, and the 596 597 level of scrutiny proportionate to the risk classification of the medical device.

598

#### 599 Acknowledgements

- 600 The authors would like to acknowledge the cooperation of the staff at NRA IN Zimbabwe for
- 601 their assistance during the interviews and availing the evidence for the assessment to be
- 602 successiful.

603

## 604 **References**

- Sabet Sarvestani A, Sienko KH. Medical device landscape for communicable and noncommunicable diseases in low-income countries [Internet]. Vol. 14, Globalization and Health. Global Health; 2018 [cited 2022 Jul 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/29973232/
- World Health Organization. WHO global model regulatory framework for medical devices including in vitro diagnostic medical devices. [Internet]. WHO Medical device technical series. Licence: CC BY-NC-SA 3.0 IGO. 2017. 68 p. Available from: https://www.who.int/medical\_devices/publications/global\_model\_regulatory\_framewo rk meddev/en/
- GHTF. Global Harmonization Task Force Study Group 1: Definition of the Terms
  'Medical Device' and 'In Vitro Diagnostic (IVD) Medical Device.' Force, Study Gr 1
  Glob Harmon Task [Internet]. 2012;(Ivd):6. Available from:
  http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n071-2012definition-of-terms-120516.pdf#search=%22ghtf definition ?Medical Device?
  2012%22
- European Commission. Regulation (EU) 2017/745 of The European Parliament and of
  the Council on Medical Devices. Off J Eur Union. 2017;5(8):175.
- European Commission. Regulation (EU) 2017/746 of the European parliament and of
  the council on in vitro diagnostic medical devices. Off J Eur Union. 2017;5(5):117–76.
- 624 6. REGULATORY AFFAIRS PROFESSIONALS SOCIETY.
  625 Fundamentals\_of\_Medical\_Device\_Regulations\_Fifth\_.pdf. Fifth. Hall GN, editor.
  626 Rockville: RAPS BOOKS; 2022. 748 p.
- Jarow JP, Baxley JH. Medical devices: US medical device regulation [Internet]. Vol.
  33, Urologic Oncology: Seminars and Original Investigations. Urol Oncol; 2015 [cited
  2022 Jul 30]. p. 128–32. Available from: https://pubmed.ncbi.nlm.nih.gov/25458071/
- 630 8. Campillo-Artero C. A full-fledged overhaul is needed for a risk and value-based
  631 regulation of medical devices in Europe. Health Policy (New York). 2013 Nov
  632 1;113(1-2):38-44.
- 9. Hubner S, Maloney C, Phillips SD, Doshi P, Mugaga J, Ssekitoleko RT, et al. The
  evolving landscape of medical device regulation in East, Central, and Southern Africa.
  Glob Heal Sci Pract [Internet]. 2021 Apr 1 [cited 2021 Nov 10];9(1):136–48.
  Available from: https://pubmed.ncbi.nlm.nih.gov/33764886/
- 10. De Maria C, Di Pietro L, Díaz Lantada A, Madete J, Makobore PN, Mridha M, et al.
  Safe innovation: On medical device legislation in Europe and Africa. Heal Policy
  Technol [Internet]. 2018;7(2):156–65. Available from:
  https://doi.org/10.1016/j.hlpt.2018.01.012

641 642 643	11.	Addae-Mensah I, Beltramini H, Haggag AA, Hoogmartens J, Shaohong J, Molzon JA, et al. WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organization - Technical Report Series. 2006.
644 645 646 647	12.	World Health Organization. Health products policy and standards : Good Manufacturing Practices [Internet]. 2018 [cited 2023 May 21]. Available from: https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical- technology/medical-devices/regulations
648 649 650 651 652	13.	Dube-Mwedzi S, Kniazkov S, Nikiema JB, Kasilo OMJ, Fortin A, Tumusiime P, et al. A rapid assessment of the National Regulatory Systems for medical products in the Southern African Development Community [Internet]. Vol. 13, Journal of Pharmaceutical Policy and Practice. J Pharm Policy Pract; 2020 [cited 2021 Nov 10]. Available from: https://pubmed.ncbi.nlm.nih.gov/33029353/
653 654 655 656 657	14.	Kniazkov S, Dube-Mwedzi S, Nikiema JB. Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community [Internet]. Vol. 13, Journal of Pharmaceutical Policy and Practice. J Pharm Policy Pract; 2020 [cited 2022 Jul 29]. Available from: https://pubmed.ncbi.nlm.nih.gov/33088577/
658 659 660 661 662 663	15.	Kniazkov S, Dube-Mwedzi S, Nikiema JB. Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community [Internet]. Vol. 13, Journal of Pharmaceutical Policy and Practice. John Wiley & Sons, Ltd; 2020 [cited 2021 Sep 19]. p. e25229. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25229
664 665 666	16.	Guzman J, O'Connell E, Kikule K, Hafner T. The WHO Global Benchmarking Tool: A game changer for strengthening national regulatory capacity [Internet]. Vol. 5, BMJ Global Health. 2020. p. 3181. Available from: http://gh.bmj.com/
667 668 669	17.	MCAZ. Chapter 15: 03 MEDICINES AND ALLIED SUBSTANCES CONTROL ACT [Internet]. 2014. Available from: https://www.mcaz.co.zw/index.php/downloads/category/7-regulations
670 671 672 673	18.	Khadem Broojerdi A, Baran Sillo H, Ostad Ali Dehaghi R, Ward M, Refaat M, Parry J. The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage. Front Med. 2020 Aug 19;7:457.
674 675 676 677 678 679	19.	World Health Organization. Manual for benchmarking of the national regulatory system of medical products and formulation of institutional development plans. 2021;(February):1–81. Available from: https://cdn.who.int/media/docs/default-source/medicines/regulation-systems/benchmarking_manual_v2_09mar2021_clean.pdf?sfvrsn=33b0038d_5&down load=true
680 681	20.	Andrews M, Pritchett L, Woolcock M. Escaping Capability Traps Through Problem Driven Iterative Adaptation (PDIA). World Dev. 2013;51(June 2012):234–44.
682 683 684	21.	Global Harmonization Task Force. Principles of Medical Devices Classification. 2006;1–27. Available from: https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-

685		n15-2006-guidance-classification-060627.pdf
686 687 688 689	22.	(MDCG) MDCG. Guidance on classification of medical devices. Mdcg 2021-24 [Internet]. 2021 [cited 2022 Jul 29];1–11. Available from: https://health.ec.europa.eu/latest-updates/updated-joint-implementation-plan-actions- considered-necessary-ensure-sound-functioning-new-2022-02-07_en
690 691 692	23.	Sweileh WM. Substandard and falsified medical products: bibliometric analysis and mapping of scientific research. Global Health [Internet]. 2021 Dec 1 [cited 2022 Jul 29];17(1). Available from: https://pubmed.ncbi.nlm.nih.gov/34556126/
693 694	24.	Barrow JM, Brannan GD, Khandhar PB. Research Ethics. StatPearls [Internet]. 2022 [cited 2023 Feb 4]; Available from: https://pubmed.ncbi.nlm.nih.gov/29083578/
695 696	25.	Bridges W. The Creation of a Competent Global Regulatory Workforce. Front Pharmacol. 2019;10(March):1–6.
697 698	26.	RAPS. Regulatory Competency Framework. 2021 [cited 2022 Jul 28]; Available from: https://www.raps.org/resources/regulatory-competency-framework
699		
700		



RS= Regulatory System, MA: Market Authorisation, VL: Vigilance, MC: Market Surveillance and Control,

LI: Licensing Establishment, RI: Regulatory Inspection, LT: Laboratory Testing, CT: Clinical Trials

## Figure 1. The Maturity Level for the Regulatory Functions assessed at MCAZ between June and August 2022.

# Figure




Figure 2: Quality of Implementation of regulatory functions at MCAZ between June and August 2022.

# Figure